APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

HIV Antivirals

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global HIV Antivirals Industry Growth and Trends Forecast to 2032

Report ID 173998770127 December 202590 pages

Choose your research edition.

Industry ResearchHIV Antivirals Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Antivirals Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal HIV Antivirals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Antivirals Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Antivirals Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global HIV Antivirals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for HIV Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for HIV Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of HIV Antivirals include Teva Pharmaceuticals, Merck & Co., Roche, Gilead Sciences, AbbVie, ViiV Healthcare, Johnson & Johnson (Janssen Pharmaceuticals) and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global HIV Antivirals market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The HIV Antivirals market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global HIV Antivirals market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to HIV Antivirals.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global HIV Antivirals market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

HIV Antivirals Market by Company

Teva Pharmaceuticals

Merck & Co.

Roche

Gilead Sciences

AbbVie

ViiV Healthcare

Johnson & Johnson (Janssen Pharmaceuticals)

Bristol-Myers Squibb

HIV Antivirals Segment by Type

Protease Inhibitors (Pls)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)

Fixed Dose Combinations (FDCs)

Nucleoside Reverse Transcriptase lnhibitors (NRTls)

Entry Inhibitors -CCR5 co-receptor antagonist

Integrase Strand Transfer Inhibitors (lNSTls)

Others

HIV Antivirals Segment by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

HIV Antivirals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Antivirals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Antivirals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Antivirals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of HIV Antivirals manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of HIV Antivirals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Protease Inhibitors (Pls) Table 2. Major Company of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls) Table 3. Major Company of Fixed Dose Combinations (FDCs) Table 4. Major Company of Nucleoside Reverse Transcriptase lnhibitors (NRTls) Table 5. Major Company of Entry Inhibitors -CCR5 co-receptor antagonist Table 6. Major Company of Integrase Strand Transfer Inhibitors (lNSTls) Table 7. Major Company of Others Table 8. Global HIV Antivirals Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global HIV Antivirals Sales by Type (2021-2026) & (K Units) Table 10. Global HIV Antivirals Sales Market Share in Volume by Type (2021-2026) Table 11. Global HIV Antivirals Sales by Type (2021-2026) & (US$ Million) Table 12. Global HIV Antivirals Sales Market Share in Value by Type (2021-2026) Table 13. Global HIV Antivirals Price by Type (2021-2026) & (US$/Unit) Table 14. Global HIV Antivirals Sales by Type (2027-2032) & (K Units) Table 15. Global HIV Antivirals Sales Market Share in Volume by Type (2027-2032) Table 16. Global HIV Antivirals Sales by Type (2027-2032) & (US$ Million) Table 17. Global HIV Antivirals Sales Market Share in Value by Type (2027-2032) Table 18. Global HIV Antivirals Price by Type (2027-2032) & (US$/Unit) Table 19. North America HIV Antivirals Sales by Type (2021-2026) & (K Units) Table 20. North America HIV Antivirals Sales by Type (2021-2026) & (US$ Million) Table 21. Europe HIV Antivirals Sales by Type (2021-2026) & (K Units) Table 22. Europe HIV Antivirals Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific HIV Antivirals Sales by Type (2021-2026) & (K Units) Table 24. Asia-Pacific HIV Antivirals Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America HIV Antivirals Sales by Type (2021-2026) & (K Units) Table 26. Latin America HIV Antivirals Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa HIV Antivirals Sales by Type (2021-2026) & (K Units) Table 28. Middle East and Africa HIV Antivirals Sales by Type (2021-2026) & (US$ Million) Table 29. HIV Antivirals Industry Trends Table 30. HIV Antivirals Industry Drivers Table 31. HIV Antivirals Industry Opportunities and Challenges Table 32. HIV Antivirals Industry Restraints Table 33. Global HIV Antivirals Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global HIV Antivirals Revenue Market Share by Company (2021-2026) Table 35. Global HIV Antivirals Sales by Company (2021-2026) & (K Units) Table 36. Global HIV Antivirals Sales Share by Company (2021-2026) Table 37. Global HIV Antivirals Market Price by Company (2021-2026) & (US$/Unit) Table 38. Global HIV Antivirals Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global HIV Antivirals Major Company Production Sites and Headquarters Table 40. Global HIV Antivirals Company, Product Type & Application Table 41. Global HIV Antivirals Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global HIV Antivirals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global HIV Antivirals Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global HIV Antivirals Sales by Region (2021-2026) & (K Units) Table 46. Global HIV Antivirals Sales Market Share in Volume by Region (2021-2026) Table 47. Global HIV Antivirals Sales by Region (2021-2026) & (US$ Million) Table 48. Global HIV Antivirals Sales Market Share in Value by Region (2021-2026) Table 49. Global HIV Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 50. Global HIV Antivirals Sales by Region (2027-2032) & (K Units) Table 51. Global HIV Antivirals Sales Market Share in Volume by Region (2027-2032) Table 52. Global HIV Antivirals Sales by Region (2027-2032) & (US$ Million) Table 53. Global HIV Antivirals Sales Market Share in Value by Region (2027-2032) Table 54. Global HIV Antivirals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 55. Global HIV Antivirals Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global HIV Antivirals Sales by Application (2021-2026) & (K Units) Table 57. Global HIV Antivirals Sales Market Share in Volume by Application (2021-2026) Table 58. Global HIV Antivirals Sales by Application (2021-2026) & (US$ Million) Table 59. Global HIV Antivirals Sales Market Share in Value by Application (2021-2026) Table 60. Global HIV Antivirals Price by Application (2021-2026) & (US$/Unit) Table 61. Global HIV Antivirals Sales by Application (2027-2032) & (K Units) Table 62. Global HIV Antivirals Sales Market Share in Volume by Application (2027-2032) Table 63. Global HIV Antivirals Sales by Application (2027-2032) & (US$ Million) Table 64. Global HIV Antivirals Sales Market Share in Value by Application (2027-2032) Table 65. Global HIV Antivirals Price by Application (2027-2032) & (US$/Unit) Table 66. North America HIV Antivirals Sales by Application (2021-2026) & (K Units) Table 67. North America HIV Antivirals Sales by Application (2021-2026) & (US$ Million) Table 68. Europe HIV Antivirals Sales by Application (2021-2026) & (K Units) Table 69. Europe HIV Antivirals Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific HIV Antivirals Sales by Application (2021-2026) & (K Units) Table 71. Asia-Pacific HIV Antivirals Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America HIV Antivirals Sales by Application (2021-2026) & (K Units) Table 73. Latin America HIV Antivirals Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa HIV Antivirals Sales by Application (2021-2026) & (K Units) Table 75. Middle East and Africa HIV Antivirals Sales by Application (2021-2026) & (US$ Million) Table 76. Teva Pharmaceuticals Company Information Table 77. Teva Pharmaceuticals Business Overview Table 78. Teva Pharmaceuticals HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Teva Pharmaceuticals HIV Antivirals Product Portfolio Table 80. Teva Pharmaceuticals Recent Development Table 81. Merck & Co. Company Information Table 82. Merck & Co. Business Overview Table 83. Merck & Co. HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Merck & Co. HIV Antivirals Product Portfolio Table 85. Merck & Co. Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Roche HIV Antivirals Product Portfolio Table 90. Roche Recent Development Table 91. Gilead Sciences Company Information Table 92. Gilead Sciences Business Overview Table 93. Gilead Sciences HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Gilead Sciences HIV Antivirals Product Portfolio Table 95. Gilead Sciences Recent Development Table 96. AbbVie Company Information Table 97. AbbVie Business Overview Table 98. AbbVie HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. AbbVie HIV Antivirals Product Portfolio Table 100. AbbVie Recent Development Table 101. ViiV Healthcare Company Information Table 102. ViiV Healthcare Business Overview Table 103. ViiV Healthcare HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. ViiV Healthcare HIV Antivirals Product Portfolio Table 105. ViiV Healthcare Recent Development Table 106. Johnson & Johnson (Janssen Pharmaceuticals) Company Information Table 107. Johnson & Johnson (Janssen Pharmaceuticals) Business Overview Table 108. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolio Table 110. Johnson & Johnson (Janssen Pharmaceuticals) Recent Development Table 111. Bristol-Myers Squibb Company Information Table 112. Bristol-Myers Squibb Business Overview Table 113. Bristol-Myers Squibb HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Bristol-Myers Squibb HIV Antivirals Product Portfolio Table 115. Bristol-Myers Squibb Recent Development Table 116. North America HIV Antivirals Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 117. North America HIV Antivirals Sales by Country (2021-2026) & (K Units) Table 118. North America HIV Antivirals Sales Market Share by Country (2021-2026) Table 119. North America HIV Antivirals Sales Forecast by Country (2027-2032) & (K Units) Table 120. North America HIV Antivirals Sales Market Share Forecast by Country (2027-2032) Table 121. North America HIV Antivirals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. North America HIV Antivirals Market Size by Country (2021-2026) & (US$ Million) Table 123. North America HIV Antivirals Market Share by Country (2021-2026) Table 124. North America HIV Antivirals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. North America HIV Antivirals Market Share Forecast by Country (2027-2032) Table 126. Europe HIV Antivirals Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. Europe HIV Antivirals Sales by Country (2021-2026) & (K Units) Table 128. Europe HIV Antivirals Sales Market Share by Country (2021-2026) Table 129. Europe HIV Antivirals Sales Forecast by Country (2027-2032) & (K Units) Table 130. Europe HIV Antivirals Sales Market Share Forecast by Country (2027-2032) Table 131. Europe HIV Antivirals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Europe HIV Antivirals Market Size by Country (2021-2026) & (US$ Million) Table 133. Europe HIV Antivirals Market Share by Country (2021-2026) Table 134. Europe HIV Antivirals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Europe HIV Antivirals Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific HIV Antivirals Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific HIV Antivirals Sales by Country (2021-2026) & (K Units) Table 138. Asia-Pacific HIV Antivirals Sales Market Share by Country (2021-2026) Table 139. Asia-Pacific HIV Antivirals Sales Forecast by Country (2027-2032) & (K Units) Table 140. Asia-Pacific HIV Antivirals Sales Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific HIV Antivirals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific HIV Antivirals Market Size by Country (2021-2026) & (US$ Million) Table 143. Asia-Pacific HIV Antivirals Market Share by Country (2021-2026) Table 144. Asia-Pacific HIV Antivirals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Asia-Pacific HIV Antivirals Market Share Forecast by Country (2027-2032) Table 146. Latin America HIV Antivirals Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Latin America HIV Antivirals Sales by Country (2021-2026) & (K Units) Table 148. Latin America HIV Antivirals Sales Market Share by Country (2021-2026) Table 149. Latin America HIV Antivirals Sales Forecast by Country (2027-2032) & (K Units) Table 150. Latin America HIV Antivirals Sales Market Share Forecast by Country (2027-2032) Table 151. Latin America HIV Antivirals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Latin America HIV Antivirals Market Size by Country (2021-2026) & (US$ Million) Table 153. Latin America HIV Antivirals Market Share by Country (2021-2026) Table 154. Latin America HIV Antivirals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Latin America HIV Antivirals Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa HIV Antivirals Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa HIV Antivirals Sales by Country (2021-2026) & (K Units) Table 158. Middle East and Africa HIV Antivirals Sales Market Share by Country (2021-2026) Table 159. Middle East and Africa HIV Antivirals Sales Forecast by Country (2027-2032) & (K Units) Table 160. Middle East and Africa HIV Antivirals Sales Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa HIV Antivirals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa HIV Antivirals Market Size by Country (2021-2026) & (US$ Million) Table 163. Middle East and Africa HIV Antivirals Market Share by Country (2021-2026) Table 164. Middle East and Africa HIV Antivirals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Middle East and Africa HIV Antivirals Market Share Forecast by Country (2027-2032) Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. HIV Antivirals Distributors List Table 169. HIV Antivirals Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. HIV Antivirals Image Figure 2. Global HIV Antivirals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Antivirals Market Size (2021-2032) & (US$ Million) Figure 4. Global HIV Antivirals Sales (2021-2032) & (K Units) Figure 5. Protease Inhibitors (Pls) Image Figure 6. Global Protease Inhibitors (Pls) Sales YoY Growth (2021-2032) & (K Units) Figure 7. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls) Image Figure 8. Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls) Sales YoY Growth (2021-2032) & (K Units) Figure 9. Fixed Dose Combinations (FDCs) Image Figure 10. Global Fixed Dose Combinations (FDCs) Sales YoY Growth (2021-2032) & (K Units) Figure 11. Nucleoside Reverse Transcriptase lnhibitors (NRTls) Image Figure 12. Global Nucleoside Reverse Transcriptase lnhibitors (NRTls) Sales YoY Growth (2021-2032) & (K Units) Figure 13. Entry Inhibitors -CCR5 co-receptor antagonist Image Figure 14. Global Entry Inhibitors -CCR5 co-receptor antagonist Sales YoY Growth (2021-2032) & (K Units) Figure 15. Integrase Strand Transfer Inhibitors (lNSTls) Image Figure 16. Global Integrase Strand Transfer Inhibitors (lNSTls) Sales YoY Growth (2021-2032) & (K Units) Figure 17. Others Image Figure 18. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 19. Global HIV Antivirals Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global HIV Antivirals Market Share by Type 2025 VS 2032 Figure 21. North America HIV Antivirals Sales Market Share in Volume by Type in 2025 Figure 22. North America HIV Antivirals Sales Market Share in Value by Type in 2025 Figure 23. Europe HIV Antivirals Sales Market Share in Volume by Type in 2025 Figure 24. Europe HIV Antivirals Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific HIV Antivirals Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific HIV Antivirals Sales Market Share in Value by Type in 2025 Figure 27. Latin America HIV Antivirals Sales Market Share in Volume by Type in 2025 Figure 28. Latin America HIV Antivirals Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa HIV Antivirals Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa HIV Antivirals Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 HIV Antivirals Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Hospital Pharmacies Image Figure 34. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 35. Retail Pharmacies Image Figure 36. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 37. Online Pharmacies Image Figure 38. Global Online Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 39. Global HIV Antivirals Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global HIV Antivirals Market Share by Application 2025 VS 2032 Figure 41. North America HIV Antivirals Sales Market Share in Volume by Application in 2025 Figure 42. North America HIV Antivirals Sales Market Share in Value by Application in 2025 Figure 43. Europe HIV Antivirals Sales Market Share in Volume by Application in 2025 Figure 44. Europe HIV Antivirals Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific HIV Antivirals Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific HIV Antivirals Sales Market Share in Value by Application in 2025 Figure 47. Latin America HIV Antivirals Sales Market Share in Volume by Application in 2025 Figure 48. Latin America HIV Antivirals Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa HIV Antivirals Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa HIV Antivirals Sales Market Share in Value by Application in 2025 Figure 51. North America HIV Antivirals Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. North America HIV Antivirals Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America HIV Antivirals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America HIV Antivirals Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe HIV Antivirals Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Europe HIV Antivirals Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe HIV Antivirals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe HIV Antivirals Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific HIV Antivirals Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Asia-Pacific HIV Antivirals Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific HIV Antivirals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific HIV Antivirals Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America HIV Antivirals Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Latin America HIV Antivirals Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America HIV Antivirals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America HIV Antivirals Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa HIV Antivirals Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Middle East and Africa HIV Antivirals Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa HIV Antivirals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa HIV Antivirals Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. HIV Antivirals Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. HIV Antivirals Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Protease Inhibitors (Pls)
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
  • Fixed Dose Combinations (FDCs)
  • Nucleoside Reverse Transcriptase lnhibitors (NRTls)
  • Entry Inhibitors -CCR5 co-receptor antagonist
  • Integrase Strand Transfer Inhibitors (lNSTls)
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Companies covered
  • Teva Pharmaceuticals
  • Merck & Co.
  • Roche
  • Gilead Sciences
  • AbbVie
  • ViiV Healthcare
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global HIV Antivirals Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global HIV Antivirals Sales Estimates and Forecasts (2021-2032)
  5. 1.3 HIV Antivirals Market by Type
  6. 1.3.1 Protease Inhibitors (Pls)
  7. 1.3.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
  8. 1.3.3 Fixed Dose Combinations (FDCs)
  9. 1.3.4 Nucleoside Reverse Transcriptase lnhibitors (NRTls)
  10. 1.3.5 Entry Inhibitors -CCR5 co-receptor antagonist
  11. 1.3.6 Integrase Strand Transfer Inhibitors (lNSTls)
  12. 1.3.7 Others
  13. 1.4 Global HIV Antivirals Market Size by Type
  14. 1.4.1 Global HIV Antivirals Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global HIV Antivirals Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global HIV Antivirals Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America HIV Antivirals Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe HIV Antivirals Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific HIV Antivirals Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America HIV Antivirals Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa HIV Antivirals Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 HIV Antivirals Industry Trends
  2. 2.2 HIV Antivirals Industry Drivers
  3. 2.3 HIV Antivirals Industry Opportunities and Challenges
  4. 2.4 HIV Antivirals Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by HIV Antivirals Revenue (2021-2026)
  2. 3.2 Global Top Players by HIV Antivirals Sales (2021-2026)
  3. 3.3 Global Top Players by HIV Antivirals Price (2021-2026)
  4. 3.4 Global HIV Antivirals Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global HIV Antivirals Major Company Production Sites & Headquarters
  6. 3.6 Global HIV Antivirals Company, Product Type & Application
  7. 3.7 Global HIV Antivirals Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global HIV Antivirals Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 HIV Antivirals Players Market Share by Revenue in 2025
  11. 3.8.3 2025 HIV Antivirals Tier 1, Tier 2, and Tier 3
4 HIV Antivirals Regional Status and Outlook
  1. 4.1 Global HIV Antivirals Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global HIV Antivirals Historic Market Size by Region
  3. 4.2.1 Global HIV Antivirals Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global HIV Antivirals Sales in Value by Region (2021-2026)
  5. 4.2.3 Global HIV Antivirals Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global HIV Antivirals Forecasted Market Size by Region
  7. 4.3.1 Global HIV Antivirals Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global HIV Antivirals Sales in Value by Region (2027-2032)
  9. 4.3.3 Global HIV Antivirals Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 HIV Antivirals by Application
  1. 5.1 HIV Antivirals Market by Application
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Online Pharmacies
  5. 5.2 Global HIV Antivirals Market Size by Application
  6. 5.2.1 Global HIV Antivirals Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global HIV Antivirals Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global HIV Antivirals Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America HIV Antivirals Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe HIV Antivirals Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific HIV Antivirals Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America HIV Antivirals Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa HIV Antivirals Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva Pharmaceuticals
  2. 6.1.1 Teva Pharmaceuticals Company Information
  3. 6.1.2 Teva Pharmaceuticals Business Overview
  4. 6.1.3 Teva Pharmaceuticals HIV Antivirals Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceuticals HIV Antivirals Product Portfolio
  6. 6.1.5 Teva Pharmaceuticals Recent Developments
  7. 6.2 Merck & Co.
  8. 6.2.1 Merck & Co. Company Information
  9. 6.2.2 Merck & Co. Business Overview
  10. 6.2.3 Merck & Co. HIV Antivirals Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck & Co. HIV Antivirals Product Portfolio
  12. 6.2.5 Merck & Co. Recent Developments
  13. 6.3 Roche
  14. 6.3.1 Roche Company Information
  15. 6.3.2 Roche Business Overview
  16. 6.3.3 Roche HIV Antivirals Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Roche HIV Antivirals Product Portfolio
  18. 6.3.5 Roche Recent Developments
  19. 6.4 Gilead Sciences
  20. 6.4.1 Gilead Sciences Company Information
  21. 6.4.2 Gilead Sciences Business Overview
  22. 6.4.3 Gilead Sciences HIV Antivirals Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Gilead Sciences HIV Antivirals Product Portfolio
  24. 6.4.5 Gilead Sciences Recent Developments
  25. 6.5 AbbVie
  26. 6.5.1 AbbVie Company Information
  27. 6.5.2 AbbVie Business Overview
  28. 6.5.3 AbbVie HIV Antivirals Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AbbVie HIV Antivirals Product Portfolio
  30. 6.5.5 AbbVie Recent Developments
  31. 6.6 ViiV Healthcare
  32. 6.6.1 ViiV Healthcare Company Information
  33. 6.6.2 ViiV Healthcare Business Overview
  34. 6.6.3 ViiV Healthcare HIV Antivirals Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 ViiV Healthcare HIV Antivirals Product Portfolio
  36. 6.6.5 ViiV Healthcare Recent Developments
  37. 6.7 Johnson & Johnson (Janssen Pharmaceuticals)
  38. 6.7.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Information
  39. 6.7.2 Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
  40. 6.7.3 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolio
  42. 6.7.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments
  43. 6.8 Bristol-Myers Squibb
  44. 6.8.1 Bristol-Myers Squibb Company Information
  45. 6.8.2 Bristol-Myers Squibb Business Overview
  46. 6.8.3 Bristol-Myers Squibb HIV Antivirals Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bristol-Myers Squibb HIV Antivirals Product Portfolio
  48. 6.8.5 Bristol-Myers Squibb Recent Developments
7 North America by Country
  1. 7.1 North America HIV Antivirals Sales by Country
  2. 7.1.1 North America HIV Antivirals Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America HIV Antivirals Sales by Country (2021-2026)
  4. 7.1.3 North America HIV Antivirals Sales Forecast by Country (2027-2032)
  5. 7.2 North America HIV Antivirals Market Size by Country
  6. 7.2.1 North America HIV Antivirals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America HIV Antivirals Market Size by Country (2021-2026)
  8. 7.2.3 North America HIV Antivirals Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe HIV Antivirals Sales by Country
  2. 8.1.1 Europe HIV Antivirals Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe HIV Antivirals Sales by Country (2021-2026)
  4. 8.1.3 Europe HIV Antivirals Sales Forecast by Country (2027-2032)
  5. 8.2 Europe HIV Antivirals Market Size by Country
  6. 8.2.1 Europe HIV Antivirals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe HIV Antivirals Market Size by Country (2021-2026)
  8. 8.2.3 Europe HIV Antivirals Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific HIV Antivirals Sales by Country
  2. 9.1.1 Asia-Pacific HIV Antivirals Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific HIV Antivirals Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific HIV Antivirals Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific HIV Antivirals Market Size by Country
  6. 9.2.1 Asia-Pacific HIV Antivirals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific HIV Antivirals Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific HIV Antivirals Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America HIV Antivirals Sales by Country
  2. 10.1.1 South America HIV Antivirals Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America HIV Antivirals Sales by Country (2021-2026)
  4. 10.1.3 South America HIV Antivirals Sales Forecast by Country (2027-2032)
  5. 10.2 South America HIV Antivirals Market Size by Country
  6. 10.2.1 South America HIV Antivirals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America HIV Antivirals Market Size by Country (2021-2026)
  8. 10.2.3 South America HIV Antivirals Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa HIV Antivirals Sales by Country
  2. 11.1.1 Middle East and Africa HIV Antivirals Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa HIV Antivirals Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa HIV Antivirals Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa HIV Antivirals Market Size by Country
  6. 11.2.1 Middle East and Africa HIV Antivirals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa HIV Antivirals Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa HIV Antivirals Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 HIV Antivirals Value Chain Analysis
  2. 12.1.1 HIV Antivirals Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 HIV Antivirals Production Mode & Process
  7. 12.2 HIV Antivirals Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 HIV Antivirals Distributors
  10. 12.2.3 HIV Antivirals Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst